- 2019
- News in brief - 06.08.2019
A Potential New Strategy for Treating Tumors
An international team led by Toby Lawrence, Inserm researcher at Unit 1104 Center of Immunology Marseille-Luminy (Inserm / CNRS / Aix-Marseille Université), has developed a potential therapy to reduce tumor size, where previous drugs have failed. Its findings have been published in Journal of Experimental Medicine. Tumors develop from abnormal cells in the body that […]
- Press releases - 24.07.2019
Partially hydrolysed (hypoallergenic) baby formulas do not reduce allergy risks in infants
Hypoallergenic formulas are recommended for infants who are not exclusively breastfed and who are at risk of developing allergies. While it is assumed that such formulas reduce the development of allergies later in life, it is unclear whether this claim is true. A team of INRA and INSERM researchers have shown that the consumption of partially hydrolysed (hypoallergenic) formulas was not associated with a reduced risk of developing allergies, findings that were recently published in the journal Pediatric Allergy and Immunology.
- Press releases - 18.07.2019
New prebiotics: benefits without the downsides?
A research group led by Matteo Serino, Inserm researcher at the Digestive Health Research Institute (Inserm/Inra/ENVT/UT3 Paul Sabatier), has recently shown three plant extracts to have prebiotic effects in obese/diabetic mice, with a shorter duration of treatment and at lower doses to the prebiotics currently in use.
- Press releases - 11.07.2019
High-risk pregnancy: the interferon effect
Des chercheurs ont identifié un nouveau mécanisme cellulaire qui altère la formation du placenta et pourrait ainsi provoquer des complications graves pendant la grossesse. Il est lié à la production d’interféron, une molécule qui est produite en réponse à certaines infections, notamment virales.
- Press releases - 10.07.2019
Anaphylactic shock: IgG antibodies and neutrophils play an unexpected role
Anaphylactic shock, an exacerbated allergic reaction that can prove fatal, is sometimes caused by the use of drugs during surgery. In most of these extreme reactions, evidence can be provided that patients have anti-drug antibodies of the IgE class. In 10 to 20% of anaphylactic cases evidence for the involvement of anti-drug IgE is lacking. Anti-drug IgE enable activation of mast cells and basophils that release histamine, a potent mediator involved in anaphylaxis. Teams of researchers have successfully identified a new pathological mechanism responsible for these previously unexplained cases.
- Press releases - 09.07.2019
New Antibiotics Developed by Inserm and Université de Rennes 1
Researchers from Inserm and Université de Rennes recently identified a new bacterial toxin which they transformed into potent antibiotics active against various bacteria responsible for human infections.
- Press releases - 08.07.2019
In France, 2 out of every 100 women are subjected to violence during their pregnancy
A joint team of researchers from Inserm and the University of Paris has investigated the frequency of physical abuse during pregnancy, its consequences for the mother and child, and the characteristics associated with this violence.
- Press releases - 28.06.2019
Art and Science program: Inserm at the Rencontres d’Arles and Avignon Festival
Inserm is reaching out to a new audience among the general public this summer by taking part in two events that bring together art and science in a mutually enriching way: the 8th Recherche de l’art (Art of Research) exhibition at the Rencontres d’Arles, in partnership with the École nationale supérieure de la photographie, and the 10th edition of the binôme program at the Avignon Festival, led by the Les sens des mots theater company.
- Press releases - 27.06.2019
No rest for neurons during sleep
An Inserm team has provided the first description of the behavior and language of the neurons responsible for memory consolidation during sleep.
- Press releases - 26.06.2019
Acting on the immune system even before cancer develops may be feasible
Researchers have shown that using immunotherapies at very early stages could potentially help prevent cancer.